glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and acute

doi: 10.1016/j.immuni.2013.11.010 40 OuyangWRutzSCrellinNKValdezPAHymowitzSG

Healthcare providers may prescribe these injections to support weight-loss plans, boost exercise endurance, or help with certain metabolic conditions

Neuroprotective effects of GLP-1 class drugs in Parkinsons disease

Baseline Oxidative Stress Individuals with high baseline oxidative stress smokers, heavy alcohol consumers, chronic disease patients, endurance athletes typically report more dramatic improvements because the deficit being corrected is larger

Detoxing may cause cells and tissues to release toxins, temporarily resolving the face or worsening zits